Recent Updates
Recently added Catalysts

RYZ101 Dose Level 1

Phase 1

SCLC,Extensive Stage | Small molecule | Other |Bristol-Myers Squibb Company|Last Updated: Aug 11, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment49
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05595460Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLCPHASE1 RECRUITING 49 — — Oct 1, 2022Mar 1, 2029Aug 11, 2025 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
RYZ101 Dose Level 1DRUGDose Level 1
RYZ101 Dose Level 2DRUGDose Level 2
RYZ101 Dose Level 3DRUGDose Level 3
RYZ101 Dose Level -1DRUGDose Level -1
AtezolizumabDRUGAtezolizumab
CarboplatinDRUGCarboplatin
EtoposideDRUGEtoposide
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT05595460studyFirstPostDate: changed